Consensus Damora Therapeutics, Inc.

Stocks

DMRA

KYG2646Y1044

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-14 EDT			5-day change	1st Jan Change
18.43 ^USD	-0.70%		-8.94%	-19.90%

09-28	Damora Therapeutics Insider Bought Shares Worth $252,875, According to a Recent SEC Filing	MT
09-20	Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to S&P Global BMI Index	CI

Evolution of the Average Target: Damora Therapeutics, Inc.

Evolution of the Target Price: Damora Therapeutics, Inc.

Changes in Analyst Recommendations: Damora Therapeutics, Inc.

9b45.wzFOKpAHk8Ubp4-9cmfp4VK1Djx9SGLwcNkaXRwfbq0.jXt-Q_VuxoZZ7MT_OCqKvmLwOQ5OZQuACu5pLF8nDdSzcz0T_j7qlVbi6A~d29ead499039766a5b3667782017b53a

Analysts' recommendations: Damora Therapeutics, Inc.

07-29	Wedbush Adjusts Damora Therapeutics Price Target to $40 From $35, Maintains Outperform Rating	MT
07-27	Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target	MT
06-11	HC Wainwright Initiates Damora Therapeutics at Buy With $45 Price Target	MT
06-08	TD Cowen Initiates Damora Therapeutics at Buy	MT
05-28	Wedbush Initiates Damora Therapeutics at Outperform With $35 Price Target	MT
04-24	Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says	MT
04-24	RBC Initiates Damora Therapeutics at Outperform, Speculative Risk With $40 Price Target	MT
12-01	Guggenheim Initiates Coverage on Galecto With Buy Rating, $32 Price Target	MT
24-06-10	Oppenheimer Adjusts Price Target on Galecto to $9 From $10, Maintains Outperform Rating	MT
23-09-28	HC Wainwright Downgrades Galecto to Neutral From Buy	MT
23-08-21	HC Wainwright Adjusts Price Target on Galecto to $2 From $12, Maintains Buy Rating	MT
23-06-20	Oppenheimer Initiates Coverage on Galecto With Outperform Rating, $12 Price Target	MT
23-03-17	Cantor Fitzgerald Initiates Galecto at Overweight With $16 Price Target	MT
22-08-03	SVB Securities Adjusts Galecto's Price Target to $13 from $16, Keeps Outperform Rating	MT
22-02-14	Credit Suisse Trims Galecto's Price Target to $6 from $7, Maintains Outperform Rating	MT
21-08-06	Galecto : Credit Suisse Lowers Galecto's PT to $7 from $12 on Lower Projected Sales for GB0139, Reduced Near-Term M&A Expectations; Keeps Outperform Rating	MT
21-03-16	Galecto : Credit Suisse Lowers Galecto's PT to $12 from $29 After Recommendation to End Parts of GB0139 Phase 2 Study, Keeps Outperform Rating	MT
21-03-16	Galecto : SVB Leerink Adjusts Galecto's Price Target to $16 From $27, Keeps Outperform Rating	MT
20-11-23	Galecto : Credit Suisse Initiates Coverage on Galecto With Outperform Rating, $29 Price Target	MT
20-11-23	Galecto : BofA Securities Initiates Coverage on Galecto With Buy Rating, $21 Price Target	MT
20-11-23	Galecto : SVB Leerink Starts Galecto at Outperform With $27 Price Target	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DAMORA THERAPEUTICS, INC.					+152.63%
	WUXI APPTEC CO., LTD.					+21.23%
	ARGENX SE					+41.64%
	LONZA GROUP AG					+21.73%
	IQVIA HOLDINGS INC.					+13.73%
	REVOLUTION MEDICINES, INC.					+37.52%
	BEONE MEDICINES AG					+24.77%
	CELLTRION, INC.					+49.05%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.02%
	BIONTECH SE					+30.78%
	Average					+40.91%
	Weighted average by Cap.					+28.22%